|
Crohn Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Additionally, ileal biopsies obtained from SpA patients who developed clinically overt Crohn's disease (CD) after treatment with IL-17i (n=5) were analyzed for expression of IL-23/Th-17 related cytokines, IL-25/IL-17E-producing cells and type-2 innate lymphoid cells (ILC2s).
|
31729183 |
2020 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this review, we summarize the current evidence for both anti-IL12/23p40 and anti-IL23p19 monoclonal antibodies in CD.
|
31327402 |
2019 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
<i>STAT3</i> Genotypic Variant <i>rs744166</i> and Increased Tyrosine Phosphorylation of STAT3 in IL-23 Responsive Innate Lymphoid Cells during Pathogenesis of Crohn's Disease.
|
31321245 |
2019 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Consistently, neutralizing antibodies against IL-12/IL-23 p40 and IL-23 p19 have been successfully used in clinical trials for therapy of Crohn´s disease and pilot studies in ulcerative colitis are ongoing.
|
30563755 |
2019 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, a newly developed anti-p40 subunit of interleukin (IL)-12 and IL-23 (ustekinumab) has been recently approved in the United States for patients with moderate to severe Crohn's disease who have failed treatment with anti-TNFs.
|
31435168 |
2019 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
IL-23 is also implicated in the pathogenesis of Crohn's disease (CD) and psoriasis, both of which can occur in patients with HS.
|
31389737 |
2019 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genome wide association studies link genes of the IL-12 and IL-23 biology to both CD and UC susceptibility.
|
31158699 |
2019 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ustekinumab, a therapeutic antibody targeting both cytokines is now widely licensed for the treatment of Crohn's disease, including in Europe, the USA, Canada and Japan, whilst agents targeting IL-23 specifically are in late-phase clinical trials.
|
30478416 |
2019 |
|
Crohn Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
It is suggested that IL-23/IL-17 axis and single nucleotide polymorphisms (SNPs) of <i>IL23R</i> may have crucial role in pathogenesis of Crohn's disease (CD).
|
31052515 |
2019 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings identify IL-23 as a suitable molecular target in patients with Crohn's disease refractory to anti-TNF therapy.
|
29848778 |
2019 |
|
Crohn Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To investigate the specific single-nucleotide polymorphisms (SNPs) in genes involved in the IL-23/IL-17 axis and possible pathways that affect susceptibility to intestinal tuberculosis and Crohn's disease.
|
31171891 |
2019 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Targeting the specific p19 subunit of IL23 is a promising strategy in CD.
|
30056776 |
2018 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ustekinumab is an interleukin inhibitor which blocks the p40 subunit of IL-12 and IL-23 axis and is already approved for the treatment of Crohn's disease patients, specially those who had inadequate response or intolerance to conventional treatment with anti-TNF-α agents.
|
29846261 |
2018 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lastly, ustekinumab, a monoclonal antibody (mAb) to the p40 subunit of IL-12 and IL-23, has showed good efficacy and safety profile in patients with Crohn's disease (CD).
|
30060945 |
2018 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Areas covered: This review summarizes the available data on the role of IL-23 in CD and discusses the therapeutic relevance of blocking the function of IL-23 in this disorder.
|
30223688 |
2018 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
In parallel, we critically discuss the available data regarding the therapeutic effect of the IL-12/IL-23 inhibitors and especially of ustekinumab, a human monoclonal antibody which has been recently approved by the United States Food and Drug Administration for the management of moderate-to-severe CD and its potential to be used as first-line therapy in everyday clinical practice.
|
30271076 |
2018 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We also performed a systematic literature review for clinical studies examining the relationships between salt consumption and the development or the activity/severity of the most common IMDs mediated by the IL-23/Th17 pathway, i.e., rheumatoid arthritis (RA), multiple sclerosis (MS), and Crohn's disease (CD).
|
29740348 |
2018 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ustekinumab is a human IgG1 monoclonal antibody that targets interleukin (IL)-12 and IL-23, which may be useful in the treatment of autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn's disease.
|
29593650 |
2018 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Selective IL-23 Inhibition by Risankizumab Modulates the Molecular Profile in the Colon and Ileum of Patients With Active Crohn's Disease: Results From a Randomised Phase II Biopsy Sub-study.
|
30032288 |
2018 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ustekinumab is a monoclonal antibody targeting interleukin (IL)-12 and IL-23 and is approved for the treatment of plaque psoriasis, psoriatic arthritis, and Crohn's disease.
|
30249507 |
2018 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
One of the diseases that has benefitted most from this technology has been Crohn's disease (CD), with the identification of autophagy, the IL-17/IL-23 axis and innate lymphoid cells as key players in CD pathogenesis.
|
29484179 |
2018 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
IL-23 Blockade for Crohn s disease: next generation of anti-cytokine therapy.
|
28067059 |
2017 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The interleukin (IL)-12/IL-23 pathway has been a therapeutic target of interest in controlling active Crohn's disease (CD).
|
28838416 |
2017 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, selective blockade of interleukin-23 via inhibition of p19 might be a viable therapeutic approach in Crohn's disease.
|
28411872 |
2017 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Attenuated TNFα and IL-23 release from CD macrophages was found after infection with all E. coli strains.
|
25809337 |
2015 |